Among the 20 C-peptide positive individuals, two (10%) had mutations in HNF1A. Although the importance of diagnosing HNF1A diabetes correctly lies partly on the possibility of transferring patients from insulin to sulfonylureas, both patients couldn’t have their therapies successfully changed and were kept on insulin. This evidence concerns the gene INS and diabetes mellitus.